|Cancer Stem Cell News 7.39 October 3, 2018|
Researchers presented evidence that the difference in leukemia stem cell activity in leukemias generated from fetal liver (FL) and adult bone marrow (BM) was due to NOTCH1-driven autocrine IGF1 signaling, which was active in FL cells but restrained in BM cells by EZH2-dependent H3K27 trimethylation. They confirmed this mechanism was operative in human disease and showed that enforced IGF1 signaling effectively limited leukemia stem cell activity. [Cell Stem Cell]
Autophagy was required for niche occupancy by bam mutant stem cells. Starvation enhanced the competition of bam mutant stem cells for niche occupancy in an autophagy-dependent manner. Loss of autophagy slowed the cell cycle of bam mutant stem cells and did not influence stem cell death. [Curr Biol]
Investigators showed that deletion or depletion of C/EBPδ reduced expression of stem cell factors and stemnness markers, sphere formation and self-renewal, along with growth of tumors and established experimental metastases in vivo. [Oncogene]
Scientists report that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintained the prostate CSC subpopulation by augmenting Wnt-β-catenin signaling in prostate cancer (PCA). Downregulation of ASPM expression pronouncedly attenuated the proliferation, colony formation, and the invasive behavior of PCA cells, and dramatically reduced the number of ALDH+ CSCs and inhibited cancer stemness and tumorigenicity. [Oncogene]
ZNF322A bound directly to the c-Myc promoter and recruited histone deacetylase 3 to transcriptionally suppress c-Myc expression, which in turn increased mitochondrial oxidative phosphorylation and promoted cell motility, thus maintaining the stem cell-like properties of lung cancer. [Cell Death Differ]
Downstream analysis demonstrated that bone morphogenetic protein 4 (BMP4) controlled the expression of the survival factor ΔNp73 through its binding to BMPR1A. This resulted in the direct induction of NANOG expression and an increase of stem-like features in leukemic cells, as shown by ALDH and functional assays. [Cell Death Dis]
Compared to SIRT2– cells, SIRT2+ cells formed more tumor spheres, appeared to be more resistant towards fluorouracil-induced apoptosis, and generated bigger tumors with higher frequency after serial adoptive transplantation. [Cell Physiol Biochem]
Inhibiting integrin β8 diminished several main glioblastoma-initiating cell (GIC) characteristics and features, including self-renewal ability, stemness, migration potential and tumor formation capacity. The combination of radiotherapy and integrin β8 targeting radiosensitized GICs through post-mitotic cell death. [Mol Cancer Res]
Gli1 polyethylenimine-wrapped spherical nucleic acid nanoparticles impaired the self-renewal capacity of glioblastoma cells as indicated by a 30-40% reduction in the expression of stemness genes and further impaired the formation of stem-like neurospheres. [Mol Pharm]
FGF1 intracellular binding protein (FIBP) knockdown inhibited proliferation, enhanced chemotherapy effects, and attenuated the stemness markers of colorectal cancer cells in vivo and in vitro. GSK3β knockdown reversed the FIBP silencing-induced inhibition of proliferation and decreased stemness marker expression in HCT116-CSCs. [Oncogenesis]
The author examines long noncoding RNA (lncRNA) function in reprogrammed pluripotent cells and cancer stem cells. Because cancer stem cells arise from normal cells, their biogenesis can be viewed as a reprogramming process that occurs in vivo, and parallels between artificial reprogramming and cancer stem cell biogenesis are discussed. [Semin Cancer Biol]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
The Nobel Assembly at Karolinska Institutet awarded the 2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. [The Nobel Foundation]
Cellectar Biosciences updated interim overall survival data from the company’s ongoing Phase Ib clinical trial evaluating CLR 131 for the treatment of relapsed/refractory multiple myeloma. [Cellectar Biosciences, Inc.]
The retirement of Dr. Jeffrey Drazen as editor of the New England Journal of Medicine has created an opportunity to bring a new perspective to what is arguably the world’s most prestigious medical journal. [STAT News]
In January, U.K. Prime Minister Theresa May appointed Sam Gyimah as science and universities minister as a part of a broader cabinet reshuffle. During his visit, Gyimah spoke with Science about the United Kingdom’s withdrawal from the European Union, a topic that is causing a great deal of anxiety among U.K. scientists. [ScienceInsider]
A last-ditch attempt by biomedical science advocates to force airlines to transport nonhuman primates and other research animals appears to be facing stiff headwinds. Last week, four international carriers strongly urged the U.S. Department of Transportation to summarily reject a plea from a leading research advocacy organization to order the airlines to resume flying animals to research facilities around the world. [ScienceInsider]
NEW ESH 5th International Conference on Acute Myeloid Leukemia ‘Molecular and Translational’: Advances in Biology and Treatment
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.